RIT1 and heart failure: Importantly, two infants with RIT1-associated NS and heart failure were treated with the MEK inhibitor trametinib and showed clinically significant improvement (Andelfinger et al., 2019), suggesting that drugs targeting the RAS/MAPK pathway might be meaningful treatment options for these patients.